5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).
The reported correlation of defects in 5,10-methylenetetrahydrofolate reductase (MTHFR), the key enzyme of folate metabolism, with modulated risk for acute lymphoblastic leukemia (ALL) is ambiguous. We have elucidated the influence of MTHFR genotype on ALL development and relapse in 140 Slovenian pediatric ALL patients and 183 healthy controls. A decreased proportion of low activity MTHFR genotypes was found in a group of ALL patients with relapses compared to healthy controls (p = 0.022) and ALL cases without relapse (p = 0.027). Mutations in the MTHFR gene decrease the onset risk of ALL with relapse in the setting of no folate supplementation in pregnancy, but not of relapse-free ALL.
Karas Kuzelicki
Natasa
N
Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia.
Milek
Miha
M
Jazbec
Janez
J
Mlinaric-Rascan
Irena
I
D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D018572:Disease-Free Survival; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D045102:Methylenetetrahydrofolate Dehydrogenase (NAD+) / Q000235:genetics*; D009154:Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000473:pathology; D012008:Recurrence; D012016:Reference Values; D012189:Retrospective Studies; D012307:Risk Factors; D017524:Slovenia
D004273:DNA, Neoplasm; D045102:Methylenetetrahydrofolate Dehydrogenase (NAD+)